申请人:C4 Therapeutics, Inc.
                            
                            
                                公开号:US20210198256A1
                            
                            
                                公开(公告)日:2021-07-01
                            
                            Compounds that degrade BRD9 or MTH1 via the ubiquitin proteasome pathway in a subject in need thereof for therapeutic applications are provided. The compounds provided have an E3 Ubiquitin Ligase targeting moiety (Degron) that is linked to a Targeting Ligand for BRD9 or MTH1.